Sustained-Release Niacin with niaXtend 500 mg

Sustained-Release Niacin with niaXtend 500 mg

Doctor's Best4.7 (1,086 ratings)
Format:Tablet Quantity: 120 Tablet(s) · 120 servings
Goals

Product analysis

84 out of 100

Sustained-Release Niacin with niaXtend 500 mg provides nicotinic acid, a niacin form that can affect blood fats. Those changes do not establish better protection from heart problems, and the release format does not show an extra heart benefit.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality100

Nicotinic acid is clearly identified, helping distinguish it from other niacin forms. That clarity does not by itself establish a special benefit from sustained release.

Ingredient Transparency100

The niacin amount and exact form are clearly stated. That allows a direct comparison with other nicotinic acid preparations.

Value For Money60

Niacin offers moderate value at the serving cost. A sustained-release name alone does not establish an additional value advantage.

Customer Satisfaction81

Customer feedback is generally favorable. A substantial number of ratings supports that impression, without proving effectiveness or safety.

Product Focus68

A single active ingredient keeps the formula focused on blood-fat-related goals. Changes in blood fats do not reliably show a reduction in major heart-related outcomes.

Format
Tablet
Container
120 Tablet(s)
Per serving
$0.14
Customer rating
4.7 · 1,086 ratings
Report analysis

Goals

Cardiovascular Support
Impact
High effect
A+ Ingredient FitD+ PathwaysB- EvidenceA+ Formulation Logic
Niacin · 500 mg

Nicotinic acid can change lipid markers, which explains the saved triglyceride contribution. Its 500 mg per serving reaches the configured amount criterion, but that criterion is not a proven dose for preventing cardiovascular events. A major trial of extended-release niacin with laropiprant added to statins did not improve major vascular outcomes; this specific result does not establish every niacin product ineffective.

How this product is rated for Cardiovascular Support

Ingredient fit96

The formula contains ingredients relevant to skin nutrition. Their amounts and the presence of other actives determine how focused this finding is.
Goal fit
The relevant ingredients dominate the formula, although the product may also be linked to other goals.
Dose adequacy
The ingredients included in this finding meet the saved amount criteria; this does not establish extra benefit from larger amounts.

Pathways53

The strongest recorded coverage concerns triglyceride metabolism; this is a mechanism finding, not proof of fewer cardiovascular events.
Depth
The strongest recorded coverage concerns triglyceride metabolism; this is a mechanism finding, not proof of fewer cardiovascular events.
Breadth
One cardiovascular mechanism reaches the coverage threshold, with limited coverage of the others.

Evidence74

Vitamin B3 (Niacin) provides the strongest recognized evidence contribution, subject to the ingredient-specific population and preparation limits.
Evidence strength
Vitamin B3 (Niacin) provides the strongest recognized evidence contribution, subject to the ingredient-specific population and preparation limits.
Studied preparation
The saved result accepts the relevant preparations, although this does not establish that the finished product matches a skin trial.

Formulation logic100

The included ingredients have no recorded missing partners or configured conflicts. Amount limitations are retained separately.
Partner coverage
No missing required ingredient partner limits the saved finding; this does not establish an added combination benefit.
Conflicts
No configured ingredient conflict was identified in the supplied evaluation.
Effective doses
All ingredients included in this finding meet the saved minimum amount threshold, without proving a clinical response.
Study evidence
Niacin Supportive 136 studies
Impact
Moderate effect
A+ Ingredient FitF PathwaysC EvidenceA+ Formulation Logic

Nicotinic acid at 500 mg relates to blood-lipid metabolism. Lipid changes have not reliably translated into additional cardiovascular event reduction, and the sustained-release format should not be treated as evidence of superior heart protection.

How this product is rated for Heart Health

Ingredient fit96

The assessed ingredients are closely centered on the heart-health goal. The included amount fully meets the saved dose benchmark.
Goal fit
The assessed ingredients are closely centered on the heart-health goal.
Dose adequacy
The included amount fully meets the saved dose benchmark.

Pathways18

Lipid metabolism is the strongest mechanism in the saved findings, with partial coverage. None of the three target mechanisms reaches the saved coverage threshold.
Depth
Lipid metabolism is the strongest mechanism in the saved findings, with partial coverage.
Breadth
None of the three target mechanisms reaches the saved coverage threshold.

Evidence62

Niacin provides the strongest saved evidence rating here, with lipid effects distinct from cardiovascular event reduction. The saved assessment recognizes the preparations of the ingredients included at qualifying amounts.
Evidence strength
Niacin provides the strongest saved evidence rating here, with lipid effects distinct from cardiovascular event reduction.
Studied preparation
The saved assessment recognizes the preparations of the ingredients included at qualifying amounts.

Formulation logic100

No required ingredient partner is missing in the saved findings. No configured ingredient conflict was found in the saved assessment. All ingredients included in this finding reach the saved minimum dose threshold.
Partner coverage
No required ingredient partner is missing in the saved findings.
Conflicts
No configured ingredient conflict was found in the saved assessment.
Effective doses
All ingredients included in this finding reach the saved minimum dose threshold.
Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per servingScore
Niacin (Nicotinic Acid)
500 mg 92
Gluten Free Adults 18–50 Vegan Vegetarian
Report overview
A+ Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyC Value
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  2. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  3. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  4. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  5. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  6. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  7. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  8. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  9. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  10. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin